» Hatch-Waxman

180-Day Exclusivity: When Everybody's Special, Nobody's Special

It is very unusual for a Hatch-Waxman exclusivity issue to intersect with a Pixar movie. But a recent viewing of The Incredibles got me thinking about FDA’s 2016 final regulation regarding 180-day exclusivity, particularly its new rule that an ANDA… Read More
Read More

Court Drops Depth Charge on Submarine Exclusivity

On July 22, 2019, the United States District Court for the District of Columbia ruled against the Food and Drug Administration (“FDA”) in a lawsuit challenging FDA’s application of 3-year exclusivity in the context of a 505(b)(2) application. T… Read More
Read More

Submarine Exclusivity: Unseen Risk for 505(b)(2) Applications

Last week, the Food and Drug Administration (FDA) finalized its guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application. The final guidance provides useful tips on the differences between ANDAs and 505(b)(2) applications and the… Read More
Read More

For More Information

  • This field is for validation purposes and should be left unchanged.